Jemal A, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
Farhood B, Geraily G, Alizadeh A. Incidence and mortality of various cancers in Iran and compare to other countries: a review article. Iran J Public Health. 2018;47(3):309–16.
Mousavi SM, et al. Cancer incidence and mortality in Iran. Ann Oncol. 2009;20(3):556–63.
Almasi Z, Rafiemanesh H, Salehiniya H. Epidemiology characteristics and trends of incidence and morphology of stomach cancer in Iran. Asian Pac J Cancer Prev. 2015;16(7):2757–61.
Rohani-Rasaf M, et al. Correlation of cancer incidence with diet, smoking and socio-economic position across 22 districts of Tehran in 2008. Asian Pac J Cancer Prev. 2013;14(3):1669–766.
Forouzanfar MH, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1659–724.
Plummer M, et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4(9):e609–e616616.
Hosseini M, et al. Environmental risk factors for lung cancer in Iran: a case-control study. Int J Epidemiol. 2009;38(4):989–96.
Rastaghi S, et al. Trends and risk factors of gastric cancer in Iran (2005–2010). Int J Prev Med. 2019;10:79–79.
Abbaszadegan MR, Keyvani V, Moghbeli M. Genetic and molecular bases of esophageal cancer among Iranians: an update. Diagn Pathol. 2019;14(1):97.
Abbaszadegan MR, Moghbeli M. Genetic and molecular origins of colorectal cancer among the Iranians: an update. Diagn Pathol. 2018;13(1):97.
Moghbeli M. Genetic and molecular biology of breast cancer among Iranian patients. J Transl Med. 2019;17(1):218.
Nafissi N, et al. Epidemiology and histopathology of breast cancer in Iran versus other Middle Eastern countries. Middle East J Cancer. 2015;9(3):243–51.
Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31(1):27–36.
Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3(6):415–28.
Taft RJ, et al. Non-coding RNAs: regulators of disease. J Pathol. 2010;220(2):126–39.
Wang C, et al. LncRNA structural characteristics in epigenetic regulation. Int J Mol Sci. 2017;18(12):2659.
Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136(4):629–41.
Beroukhim R, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899–905.
Melton C, et al. Recurrent somatic mutations in regulatory regions of human cancer genomes. Nat Genet. 2015;47(7):710–6.
Guo H, et al. Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. Nat Genet. 2016;48(10):1142–50.
Majidinia M, Yousefi B. Long non-coding RNAs in cancer drug resistance development. DNA Repair. 2016;45:25–33.
Zhao X, et al. The rs6983267 SNP and long non-coding RNA CARLo-5 are associated with endometrial carcinoma. Environ Mol Mutagen. 2016;57(7):508–15.
Akers JC, et al. Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J Neurooncol. 2013;113(1):1–11.
Bolha L, Ravnik-Glavac M, Glavac D. Long noncoding RNAs as biomarkers in cancer. Dis Markers. 2017;2017:7243968.
Reis EM, Verjovski-Almeida S. Perspectives of long non-coding RNAs in cancer diagnostics. Front Genet. 2012;3:32.
Tang H, et al. Salivary lncRNA as a potential marker for oral squamous cell carcinoma diagnosis. Mol Med Rep. 2013;7(3):761–6.
Silva A, Bullock M, Calin G. The clinical relevance of long non-coding RNAs in cancer. Cancers. 2015;7(4):2169–82.
Mizrahi A, et al. Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences. J Transl Med. 2009;7:69.
Ariel I, et al. The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma. Mol Pathol. 2000;53(6):320–3.
Yang Z, et al. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann Surg Oncol. 2011;18(5):1243–50.
Tsai MC, Spitale RC, Chang HY. Long intergenic noncoding RNAs: new links in cancer progression. Cancer Res. 2011;71(1):3–7.
Beltran M, et al. A natural antisense transcript regulates Zeb2/Sip1 gene expression during Snail1-induced epithelial–mesenchymal transition. Genes Dev. 2008;22(6):756–69.
Amaral PP, et al. Complex architecture and regulated expression of the Sox2ot locus during vertebrate development. RNA. 2009;15(11):2013–27.
Askarian-Amiri ME, et al. Emerging role of long non-coding RNA SOX2OT in SOX2 regulation in breast cancer. PLoS ONE. 2014;9(7):e102140.
Qu F, Cao P. Long noncoding RNA SOX2OT contributes to gastric cancer progression by sponging miR-194-5p from AKT2. Exp Cell Res. 2018;369(2):187–96.
Shahryari A, et al. Two novel splice variants of SOX2OT, SOX2OT-S1, and SOX2OT-S2 are coupregulated with SOX2 and OCT4 in esophageal squamous cell carcinoma. Stem Cells. 2014;32(1):126–34.
Wu Y, et al. Overexpression of long non-coding RNA SOX2OT promotes esophageal squamous cell carcinoma growth. Cancer Cell Int. 2018;18:76–76.
Loewer S, et al. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet. 2010;42(12):1113–7.
Gao S, et al. ROR functions as a ceRNA to regulate Nanog expression by sponging miR-145 and predicts poor prognosis in pancreatic cancer. Oncotarget. 2016;7(2):1608–18.
Zhang A, et al. The human long non-coding RNA-RoR is a p53 repressor in response to DNA damage. Cell Res. 2013;23(3):340–50.
Takahashi K, et al. Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer. FEBS Open Bio. 2014;4:458–67.
Fan J, et al. Long non-coding RNA ROR decoys gene-specific histone methylation to promote tumorigenesis. Genome Biol. 2015;16(1):139–139.
Wang Y, et al. Endogenous miRNA sponge lincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic stem cell self-renewal. Dev Cell. 2013;25(1):69–80.
Rezaei M, et al. Altered expression of LINC-ROR in cancer cell lines and tissues. Tumor Biology. 2016;37(2):1763–9.
Wang L, et al. Linc-ROR promotes esophageal squamous cell carcinoma progression through the derepression of SOX9. J Exp Clin Cancer Res. 2017;36(1):182.
Hou P, et al. LincRNA-ROR induces epithelial-to-mesenchymal transition and contributes to breast cancer tumorigenesis and metastasis. Cell Death Dis. 2014;5(6):e1287–e12871287.
Jiang F, Zhou X, Huang J. Long non-coding RNA-ROR mediates the reprogramming in cardiac hypertrophy. PLoS ONE. 2016;11(4):e0152767.
Sahebi R, et al. Linc-ROR and its spliced variants 2 and 4 are significantly up-regulated in esophageal squamous cell carcinoma. Iran J Basic Med Sci. 2016;19(10):1131–5.
Liu X, Cui L, Liu J. Increased LincRNA ROR is association with poor prognosis for esophageal squamous cell carcinoma patients. Int J Clin Exp Pathol. 2017;10:4654–60.
Rahimnia H, et al. Overexpression of long non-coding RNA POU3F3 in esophageal squamous cell carcinoma is associated with TNM stage and family history. J Clin Basic Res. 2018;2(4):48–53.
Tong Y-S, et al. Identification of the long non-coding RNA POU3F3 in plasma as a novel biomarker for diagnosis of esophageal squamous cell carcinoma. Mol Cancer. 2015;14(1):3.
Shan T-D, et al. Knockdown of linc-POU3F3 suppresses the proliferation, apoptosis, and migration resistance of colorectal cancer. Oncotarget. 2016;7(1):961–75.
Liu HP, et al. Long noncoding RNA PCAT-1 promoted ovarian cancer cell proliferation and invasion by suppressing KLF6. Eur Rev Med Pharmacol Sci. 2019;23(11):4650–5.
Wang Y, et al. Long noncoding RNA PCAT-1 accelerates the metastasis of pancreatic cancer by repressing RBM5. Eur Rev Med Pharmacol Sci. 2019;23(17):7350–5.
Razavi M, Ghorbian S. Up-regulation of long non-coding RNA-PCAT-1 promotes invasion and metastasis in esophageal squamous cell carcinoma. EXCLI journal. 2019;18:422–8.
Shi W-H, et al. Upregulation of the long noncoding RNA PCAT-1 correlates with advanced clinical stage and poor prognosis in esophageal squamous carcinoma. Tumor Biol. 2015;36(4):2501–7.
Bayat H, et al. Two long non-coding RNAs, Prcat17.3 and Prcat38, could efficiently discriminate benign prostate hyperplasia from prostate cancer. Prostate. 2018;78(11):812–8.
Hajjari M, Salavaty A. HOTAIR: an oncogenic long non-coding RNA in different cancers. Cancer Biol Med. 2015;12(1):1–9.
Taheri M, et al. HOTAIR genetic variants are associated with prostate cancer and benign prostate hyperplasia in an Iranian population. Gene. 2017;613:20–4.
Oliveira AI, et al. Influence of HOTAIR rs920778 and rs12826786 genetic variants on prostate cancer risk and progression-free survival. Biomark Med. 2018;12(3):257–64.
Kotake Y, et al. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene. 2011;30(16):1956–62.
Yap KL, et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell. 2010;38(5):662–74.
Taheri M, et al. Association of ANRIL gene polymorphisms with prostate cancer and benign prostatic hyperplasia in an Iranian population. Biomark Med. 2017;11(5):413–22.
Zhao B, et al. Overexpression of lncRNA ANRIL promoted the proliferation and migration of prostate cancer cells via regulating let-7a/TGF-beta1/Smad signaling pathway. Cancer Biomark. 2018;21(3):613–20.
Sattarifard H, et al. Association between genetic polymorphisms of long non-coding RNA PRNCR1 and prostate cancer risk in a sample of the Iranian population. Mol Clin Oncol. 2017;7(6):1152–8.
Yang L, et al. Upregulation of long non-coding RNA PRNCR1 in colorectal cancer promotes cell proliferation and cell cycle progression. Oncol Rep. 2016;35(1):318–24.
Cheng D, et al. LncRNA PRNCR1 interacts with HEY2 to abolish miR-448-mediated growth inhibition in non-small cell lung cancer. Biomedicine Pharmacotherapy. 2018;107:1540–7.
Hong JH, et al. Correlations between genetic polymorphisms in long non-coding RNA PRNCR1 and gastric cancer risk in a Korean population. Int J Mol Sci. 2019;20(13):3355.
Li L, et al. Association between polymorphisms in long non-coding RNA PRNCR1 in 8q24 and risk of gastric cancer. Tumor Biol. 2016;37(1):299–303.
AlMutairi M, et al. Association between polymorphisms in PRNCR1 and risk of colorectal cancer in the Saudi population. PLoS ONE. 2019;14(9):e0220931.
Seitz AK, et al. Profiling of long non-coding RNAs identifies LINC00958 and LINC01296 as candidate oncogenes in bladder cancer. Sci Rep. 2017;7(1):395.
Yuan W, et al. Comprehensive analysis of lncRNA-associated ceRNA network in colorectal cancer. Biochem Biophys Res Commun. 2019;508(2):374–9.
Tano K, et al. MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes. FEBS Lett. 2010;584(22):4575–80.
Wu Y, et al. Long noncoding RNA MALAT1: insights into its biogenesis and implications in human disease. Curr Pharm Des. 2015;21(34):5017–28.
Yoshimoto R, et al. MALAT1 long non-coding RNA in cancer. Biochim Biophys Acta. 2016;1859(1):192–9.
Tripathi V, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell. 2010;39(6):925–38.
Schmidt LH, et al. Prognostic impact of bcl-2 depends on tumor histology and expression of MALAT-1 lncRNA in non-small-cell lung cancer. J Thorac Oncol. 2014;9(9):1294–304.
Luan W, et al. Long non-coding RNA MALAT1 acts as a competing endogenous RNA to promote malignant melanoma growth and metastasis by sponging miR-22. Oncotarget. 2016;7(39):63901–12.
Li HJ, et al. LncRNA UCA1 promotes mitochondrial function of bladder cancer via the MiR-195/ARL2 signaling pathway. Cell Physiol Biochem. 2017;43(6):2548–61.
Luo J, et al. LncRNA UCA1 promotes the invasion and EMT of bladder cancer cells by regulating the miR-143/HMGB1 pathway. Oncol Lett. 2017;14(5):5556–62.
Fan Y, et al. Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. FEBS J. 2014;281(7):1750–8.
Yazarlou F, et al. Urinary exosomal expression of long non-coding RNAs as diagnostic marker in bladder cancer. Cancer Manag Res. 2018;10:6357–65.
Li C, et al. High expression of long noncoding RNA MALAT1 indicates a poor prognosis and promotes clinical progression and metastasis in bladder cancer. Clin Genitourin Cancer. 2017;15(5):570–6.
Bian Z, et al. LncRNA—UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p. Sci Rep. 2016;6:23892.
Hou Z, et al. A long noncoding RNA Sox2ot regulates lung cancer cell proliferation and is a prognostic indicator of poor survival. Int J Biochem Cell Biol. 2014;53:380–8.
Farhangian P, et al. Differential expression of long non-coding RNA SOX2OT in gastric adenocarcinoma. Cancer Biomark. 2018;23(2):221–5.
Zou J-H, et al. High expression of long noncoding RNA Sox2ot is associated with the aggressive progression and poor outcome of gastric cancer. Eur Rev Med Pharmacol Sci. 2016;20:4482–6.
Zhang Y, et al. LncRNA Sox2ot overexpression serves as a poor prognostic biomarker in gastric cancer. Am J Transl Res. 2016;8(11):5035–43.
Hajjari M, et al. Up-regulation of HOTAIR long non-coding RNA in human gastric adenocarcinoma tissues. Med Oncol. 2013;30(3):670.
Emadi-Andani E, et al. Association of HOTAIR expression in gastric carcinoma with invasion and distant metastasis. Adv Biomed Res. 2014;3:135–135.
Xu Z, et al. The association of HOTAIR with the diagnosis and prognosis of gastric cancer and its effect on the proliferation of gastric cancer cells. Can J Gastroenterol Hepatol. 2019;2019:3076345.
Lu X, et al. The long noncoding RNA HOTAIR promotes colorectal cancer progression by sponging miR-197. Oncol Res. 2018;26(3):473–81.
Luo Z-F, et al. Clinical significance of HOTAIR expression in colon cancer. World J Gastroenterol. 2016;22(22):5254–9.
Katsushima K, et al. Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment. Nat Commun. 2016;7:13616.
Niu Y, et al. Long non-coding RNA TUG1 is involved in cell growth and chemoresistance of small cell lung cancer by regulating LIMK2b via EZH2. Mol Cancer. 2017;16(1):5.
Baratieh Z, et al. Aberrant expression of PlncRNA-1 and TUG1: potential biomarkers for gastric cancer diagnosis and clinically monitoring cancer progression. Biomark Med. 2017;11(12):1077–90.
Dong L, et al. Upregulation of long non-coding RNA PlncRNA-1 promotes metastasis and induces epithelial-mesenchymal transition in hepatocellular carcinoma. Cell Physiol Biochem. 2016;38(2):836–46.
Zhang E, et al. Increased expression of long noncoding RNA TUG1 predicts a poor prognosis of gastric cancer and regulates cell proliferation by epigenetically silencing of p57. Cell Death Dis. 2016;7(2):e2109.
Guo X, et al. GAS5 inhibits gastric cancer cell proliferation partly by modulating CDK6. Oncol Res Treat. 2015;38(7–8):362–6.
Liu Y, et al. Long non-coding RNA GAS5 inhibits migration and invasion in gastric cancer via interacting with p53 protein. Dig Liver Dis. 2019. https://doi.org/10.1016/j.dld.2019.08.012.
Liu Y, et al. lncRNA GAS5 enhances G1 cell cycle arrest via binding to YBX1 to regulate p21 expression in stomach cancer. Sci Rep. 2015;5:10159.
Aminian K, et al. A functional genetic variant in GAS5 lncRNA (rs145204276) modulates p27Kip1 expression and confers risk for gastric cancer. Br J Biomed Sci. 2019;76(2):83–5.
Li Q, et al. Polymorphism in the promoter region of lncRNA GAS5 is functionally associated with the risk of gastric cancer. Clin Res Hepatol Gastroenterol. 2018;42(5):478–82.
Zhao X, et al. Gas5 exerts tumor-suppressive functions in human glioma cells by targeting miR-222. Mol Ther. 2015;23(12):1899–911.
Kangarlouei R, et al. ANRIL and ANRASSF1 long noncoding RNAs are upregulated in gastric cancer. J Cell Biochem. 2019;120(8):12544–8.
Guan H, et al. Downregulation of lncRNA ANRIL suppresses growth and metastasis in human osteosarcoma cells. Oncotargets Ther. 2018;11:4893–9.
Zhao W, Luo J, Jiao S. Comprehensive characterization of cancer subtype associated long non-coding RNAs and their clinical implications. Sci Rep. 2014;4:6591.
Yi L, et al. Long noncoding RNA PTPRG-AS1 acts as a microRNA-194-3p sponge to regulate radiosensitivity and metastasis of nasopharyngeal carcinoma cells via PRC1. J Cell Physiol. 2019;234(10):19088–102.
Taheri M, Ghafouri-Fard S. Antisense non-coding RNA in the INK4 locus (ANRIL) in human cancers. Int J Cancer Manag. 2018;11(10):e67864.
Iranpour M, et al. Expression analysis of four long noncoding RNAs in breast cancer. Tumor Biol. 2016;37(3):2933–40.
Meseure D, et al. Expression of ANRIL-polycomb complexes-CDKN2A/B/ARF genes in breast tumors: identification of a two-gene (EZH2/CBX7) signature with independent prognostic value. Mol Cancer Res. 2016;14(7):623–33.
Xu C, et al. Long noncoding RNA PTPRG-AS1 regulates growth of glioma cells by sponging miR-185-5p. RSC Adv. 2019;9(19):10870–80.
Hassanzarei S, et al. Genetic polymorphisms of HOTAIR gene are associated with the risk of breast cancer in a sample of southeast Iranian population. Tumour Biol. 2017;39(10):1010428317727539.
Bayram S, et al. Effect of HOTAIR rs920778 polymorphism on breast cancer susceptibility and clinicopathologic features in a Turkish population. Tumour Biol. 2015;36(5):3863–70.
Yang F, et al. Up-regulated long non-coding RNA H19 contributes to proliferation of gastric cancer cells. FEBS J. 2012;279(17):3159–65.
Hou J, et al. Long noncoding RNA H19 upregulates vascular endothelial growth factor A to enhance mesenchymal stem cells survival and angiogenic capacity by inhibiting miR-199a-5p. Stem Cell Res Ther. 2018;9(1):109.
Hassanzarei S, et al. Genetic polymorphisms in long noncoding RNA H19 are associated with breast cancer susceptibility in Iranian population. Meta Gene. 2017;14:1–5.
Safari MR, et al. Genomic variants within the long non-coding RNA H19 confer risk of breast cancer in Iranian population. Gene. 2019;701:121–4.
Abdollahzadeh S, Ghorbian S. Association of the study between LncRNA-H19 gene polymorphisms with the risk of breast cancer. J Clin Lab Anal. 2019;33(3):e22826.
Lin Y, et al. Genetic variants in long noncoding RNA H19 contribute to the risk of breast cancer in a southeast China Han population. Onco Targets Ther. 2017;10:4369–78.
Qin W, et al. Functional polymorphisms of the lncRNA H19 promoter region contribute to the cancer risk and clinical outcomes in advanced colorectal cancer. Cancer Cell Int. 2019;19:215–215.
Li L, et al. Association between H19 SNP rs217727 and lung cancer risk in a Chinese population: a case control study. BMC Med Genet. 2018;19(1):136.
Adriaenssens E, et al. H19 Overexpression in breast adenocarcinoma stromal cells is associated with tumor values and steroid receptor status but independent of p53 and Ki-67 expression. Am J Pathol. 1998;153(5):1597–607.
Sheng L, et al. New insights into the long non-coding RNA SRA: physiological functions and mechanisms of action. Front Med. 2018;5:244–244.
Kino T, et al. Noncoding RNA Gas5 is a growth arrest- and starvation-associated repressor of the glucocorticoid receptor. Sci Signal. 2010;3(107):ra8.
Wang L, et al. Down-regulation of lncRNA GAS5 attenuates neuronal cell injury through regulating miR-9/FOXO3 axis in cerebral ischemic stroke. RSC Adv. 2019;9(28):16158–66.
Sasaki YTF, et al. MENε/β noncoding RNAs are essential for structural integrity of nuclear paraspeckles. Proc Natl Acad Sci. 2009;106(8):2525–30.
Zhang P, et al. The lncRNA Neat1 promotes activation of inflammasomes in macrophages. Nat Commun. 2019;10(1):1495.
Arshi A, et al. Expression analysis of MALAT1, GAS5, SRA, and NEAT1 lncRNAs in breast cancer tissues from young women and women over 45 years of age. Mol Ther Nucleic Acids. 2018;12:751–7.
Huang XJ, et al. MALAT1 promotes angiogenesis of breast cancer. Oncol Rep. 2018;40(5):2683–9.
Li S, et al. Long noncoding RNA GAS5 suppresses triple negative breast cancer progression through inhibition of proliferation and invasion by competitively binding miR-196a-5p. Biomed Pharmacother. 2018;104:451–7.
Yan R, et al. Genetic variants in lncRNA SRA and risk of breast cancer. Oncotarget. 2016;7(16):22486–96.
Shin VY, et al. Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness. Cell Death Dis. 2019;10(4):270.
Soleimanpour E, et al. Evaluating long non-coding RNA PRNCR1 in breast cancer. J Fasa Univ Med Sci. 2018;8(1):637–46.
Babaei E, Hoseinpour Feizi MA. Study of the differential expression of non-coding RNA, such as PRNCR1, in the plasma of breast cancer patients. Sci J Ilam Univ Med Sci. 2019;26(5):71–8.
Kholdi S, et al. Non-coding RNA NAV2-AS2 and the risk of lobular carcinoma in breast. Biomed Health. 2018;3(1):46–53.
Ravanbakhsh R, et al. Clinical and in vitro study of novel long non-coding RNA lncUSMycN in breast cancer. Iran Biomed J. 2018;23:303–11.
Gong H, et al. High expression of long non-coding RNA ZEB1-AS1 promotes colorectal cancer cell proliferation partially by suppressing p15 expression. Tumour Biol. 2017;39(6):1010428317705336.
Rezanejad Bardaji H, Asadi MH, Yaghoobi MM. Long non-coding RNA ZEB1-AS1 promotes tumorigenesis and metastasis in colorectal cancer. J Genet Resour. 2018;4(1):1–6.
Lv S-Y, et al. The lncRNA ZEB1-AS1 sponges miR-181a-5p to promote colorectal cancer cell proliferation by regulating Wnt/β-catenin signaling. Cell Cycle. 2018;17(10):1245–54.
Kazemzadeh M, et al. Misregulation of the dependence receptor DCC and its upstream lincRNA, LOC100287225, in colorectal cancer. Tumori J. 2015;103(1):40–3.
Kazemzadeh M, et al. LOC100287225, novel long intergenic non-coding RNA, misregulates in colorectal cancer. Cancer Biomark. 2016;16(3):499–505.
Rezanejad Bardaji H, Asadi MH, Yaghoobi MM. Long noncoding RNA VIM-AS1 promotes colorectal cancer progression and metastasis by inducing EMT. Eur J Cell Biol. 2018;97(4):279–88.
Gong J, et al. A functional polymorphism in lnc-LAMC2-1:1 confers risk of colorectal cancer by affecting miRNA binding. Carcinogenesis. 2016;37(5):443–51.
Hashemi M, et al. Association of lnc-LAMC2-1:1 rs2147578 and CASC8 rs10505477 polymorphisms with risk of childhood acute lymphoblastic leukemia. Asian Pac J Cancer Prev. 2016;17(11):4985–9.
Deng J, et al. Long non-coding RNA OIP5-AS1 functions as an oncogene in lung adenocarcinoma through targeting miR-448/Bcl-2. Biomed Pharmacother. 2018;98:102–10.
Kim J, et al. LncRNA OIP5-AS1/cyrano sponges RNA-binding protein HuR. Nucleic Acids Res. 2016;44(5):2378–92.
Zhang J, et al. LncRNA OIP5-AS1 promotes the proliferation of hemangioma vascular endothelial cells via regulating miR-195-5p/NOB1 axis. Front Pharmacol. 2019;10:449.
Esfandi F, et al. Expression analysis of OIP5-AS1 in non-small cell lung cancer. Klin Onkol. 2018;31(4):260–3.
Wang M, et al. Long non-coding RNA OIP5-AS1 promotes proliferation of lung cancer cells and leads to poor prognosis by targeting miR-378a-3p. Thorac Cancer. 2018;9(8):939–49.